The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.
Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital at Mölndal, University of Gothenburg, 43180, Mölndal, Sweden.
Parkinsonism Relat Disord. 2018 Apr;49:4-8. doi: 10.1016/j.parkreldis.2018.01.018. Epub 2018 Jan 31.
Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker for Parkinson's disease (PD), but little is known about the evolution of this marker during the course of the disease. Our objective was to investigate whether CSF total α-synuclein concentrations change over time and are associated with motor and cognitive function in PD.
CSF total α-synuclein concentrations were quantified in 56 longitudinally followed PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects were included as controls. The samples were analyzed using two independent, validated ELISA methods: our recently developed and validated in-house ELISA and a commercial kit from BioLegend.
CSF total α-synuclein levels did not distinguish PD patients from controls, displayed no substantial changes during a period of up to 4 years, and did not predict subsequent motor or cognitive decline. These findings were consistent for both analytical methods.
Our findings do not support the clinical utility of total α-synuclein as a single diagnostic or prognostic biomarker in PD.
脑脊液（CSF）总α-突触核蛋白被认为是帕金森病（PD）的潜在生物标志物，但关于该标志物在疾病过程中的演变知之甚少。我们的目的是研究 CSF 总α-突触核蛋白浓度是否随时间变化，以及与 PD 患者的运动和认知功能相关。
对 56 例纵向随访的 PD 患者进行 CSF 总α-突触核蛋白浓度定量分析，其中 27 例患者在 2 年和/或 4 年后重复提供 CSF。另外 18 名受试者作为对照组。使用两种独立的、经过验证的 ELISA 方法分析样本：我们最近开发并验证的内部 ELISA 和来自 BioLegend 的商业试剂盒。
CSF 总α-突触核蛋白水平不能区分 PD 患者和对照组，在长达 4 年的时间内没有明显变化，也不能预测随后的运动或认知下降。这两种分析方法的结果一致。
我们的研究结果不支持 CSF 总α-突触核蛋白作为 PD 的单一诊断或预后生物标志物的临床效用。
